Eligibility Criteria

Patient Population

Nefropatía por IgA

Age

18 — 26+

History of transplant allowed?

No

History of dialysis allowed?

No

eGFR

60

UPCR

Not Sure

Permitted medication history

Ace Inhibitors/ARB, Prednisone (Steroids), Rituximab (AKA Rituxan), Other

Patient should be

Neither of These

About the Drug

What is involved for the patient

During the study you would first be screened to make sure you are eligible for treatment. If so, you would be placed by chance in a group to receive one of the Felzartamab or placebo doses. A placebo looks like the study treatment but has no actual medicine in it. A placebo is used to evaluate any potential difference in the benefits and side effects of felzartamab. The medicine and placebo are given as intravenous (IV) infusions, which means they are given slowly through a small needle in the arm. Each participant would receive a total of 9 infusions. You would also continue to take your current standard medicine (for example, blood pressure pills).
The study lasts a little over 2 years with 17 visits for tests. It comprises the screening period, treatment period and follow-up period in which you will allow the sponsor to access your medical history and biosamples such as blood and urine and perhaps biopsy tissue will be collected.

Sponsor

MorphoSys AG

Estimated End Date

Last patient last visit January 2024

About the Trial

Study Drug

MOR202/Felzartamab

Study Goal

IGNAZ seeks to investigate an innovative treatment option for IgA Nephropathy

About the drug or intervention

Felzartamab belongs to a group of medicines called “monoclonal antibodies”, proteins designed to attach to specific cells or substances in the body. Felzartamab is designed to attach to the cells that produce the antibody in your body and subsequently reduce unwanted auto-antibodies considered responsible for the development of IgA nephropathy.